Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) FLT3 Antibodies:
anti-Human FLT3 Antibodies:
anti-Rat (Rattus) FLT3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal FLT3 Primary Antibody for FACS - ABIN2688960
Mackarehtschian, Hardin, Moore, Boast, Goff, Lemischka: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. in Immunity 1995
Show all 4 Pubmed References
Human Polyclonal FLT3 Primary Antibody for IF - ABIN362818
Sekine, Kataoka, Fukuyama, Adachi, Davydova, Yamamoto, Kobayashi, Fujihashi, Suzuki, Curiel, Shizukuishi, McGhee, Fujihashi: A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 5 Pubmed References
Human Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900037
Armstrong, Kung, Mabon, Silverman, Stam, Den Boer, Pieters, Kersey, Sallan, Fletcher, Golub, Griffin, Korsmeyer: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. in Cancer cell 2003
Show all 2 Pubmed References
Human Monoclonal FLT3 Primary Antibody for IHC, ELISA - ABIN1724846
Pereira de Sousa, Berthault, Granato, Dias, Ramond, Kee, Cumano, Vieira: Inhibitors of DNA binding proteins restrict T cell potential by repressing Notch1 expression in Flt3-negative common lymphoid progenitors. in Journal of immunology (Baltimore, Md. : 1950) 2012
Show all 2 Pubmed References
Human Monoclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900035
Williams, Li, Nguyen, Brown, Levis, Small: Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. in Blood 2012
Mouse (Murine) Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900092
Arora, Stopp, Böhmer, Schons, Godfrey, Masson, Razumovskaya, Rönnstrand, Tänzer, Bauer, Böhmer, Müller: Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. in The Journal of biological chemistry 2011
Mouse (Murine) Monoclonal FLT3 Primary Antibody for FACS - ABIN4272599
Caldarelli, Müller, Paskowski-Rogacz, Herrmann, Bauer, Koch, Heninger, Krastev, Ding, Kasper, Fischer, Brodhun, Böhmer, Buchholz: A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. in Leukemia 2013
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN1302921
Whartenby, Calabresi, McCadden, Nguyen, Kardian, Wang, Mosse, Pardoll, Small: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. in Proceedings of the National Academy of Sciences of the United States of America 2005
Show all 5 Pubmed References
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN489931
Kuchenbauer, Kern, Schoch, Kohlmann, Hiddemann, Haferlach, Schnittger: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. in Haematologica 2005
Show all 5 Pubmed References
Acute myeloid leukemia (show BCL11A Antibodies) tumor cell lines expressing the D835Y activation loop mutation of FLT3 failed to form colonies.
Flt3 was heterogeneously expressed by almost all of the hematopoietic stem cell compartments.
SLAP2 acts as a negative regulator of FLT3 signaling and therefore, modulation of SLAP2 expression levels may provide an alternative therapeutic approach for FLT3-ITD positive acute myeloid leukemia (show BCL11A Antibodies)
Data show that conditional deletion of Dnmt3a (show DNMT3A Antibodies) and simultaneous "knock in" of Flt3ITD/+, cooperate to drive leukemia development at a faster rate than Dnmt3a (show DNMT3A Antibodies) loss alone.
ATM (show ATM Antibodies)/G6PD (show G6PD Antibodies)-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia (show BCL11A Antibodies) that can be successfully reversed.
Flt3 and cooperating Flt3/Runx1 mutations cause hematopoietic stem cell depletion and myeloid progenitor expansion during adult but not fetal stages of murine development.
Tumor necrosis factor (TNF (show TNF Antibodies)), a cell-extrinsic potent negative regulator of hematopoietic stem cells (HSCs), was overexpressed in bone marrow niche cells from FLT3 internal tandem duplications (FLT3 ITDs) mice.
the angiogenic factor (show VEGFA Antibodies) Egfl7 (show EGFL7 Antibodies) activates the Flt3/Flt3 ligand (show FLT3LG Antibodies) pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity
the Hoxa9 (show HOXA9 Antibodies)- and Meis1 (show MEIS1 Antibodies)-associated upregulation of Flt3 is a passive event with regard to leukemia development in mice and with limited relevance to the AML (show RUNX1 Antibodies) pathology.
lineage-specific STAT5 (show STAT5A Antibodies) activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype in mice
Multivariate Cox's proportional hazards regression analyses revealed that OCT4 (show POU5F1 Antibodies) mRNA high expression was an independent predictive factor for shorter EFS (show EFS Antibodies) and OS in AML (show RUNX1 Antibodies) patients. Conclusion OCT4 (show POU5F1 Antibodies) correlates with presence of CK, FLT3-ITD mutation and poorer risk stratification, and it could be served as a convincing biomarker for predicting unfavourable prognosis in AML (show RUNX1 Antibodies) patients.
Results indicate that DNMT3A (show DNMT3A Antibodies) mutations alone do not affect the clinical outcomes of AML (show RUNX1 Antibodies) patients undergoing allogeneic HSCT, but when accompanied by FLT3-ITD mutations, the OS was significantly reduced (5-year OS 0% for DNMT3A (show DNMT3A Antibodies) R882mut/FLT3-ITDpos patients vs. 62% DNMT3A (show DNMT3A Antibodies) R882wt/FLT3-ITDneg, p=0.025) and the relapse rate increased.
RIPK3 (show RIPK3 Antibodies)-dependent cell death and inflammasome activation in FLT3-internal-tandem-duplication-expressing leukemia-initiating cells
The results suggested that FLT3 ITD mutations could become an indicator of poor prognosis of APL (show FASL Antibodies), and these patients should receive more intensive therapy according to current guidelines.
Low FLT3 expression is associated with Pancreatic ductal adenocarcinoma.
DNMT3A (show DNMT3A Antibodies) R882 mutation plays an important role in CN-AML (show RUNX1 Antibodies) patients' prognosis and clinical outcomes in the presence and absence of NPM1 (show NPM1 Antibodies) and FLT3 mutations.
the FLT3 inhibitor AC220 inhibited glutamine (show GFPT1 Antibodies) flux into the antioxidant factor glutathione profoundly due to defective glutamine (show GFPT1 Antibodies) import.
Mutation in FLT3 gene is associated with Acute Myeloid Leukemia (show BCL11A Antibodies).
Acute myeloid leukemia (show BCL11A Antibodies) harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AML (show RUNX1 Antibodies)(FLT3-ITD)) is associated with poor prognosis.
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia (show BCL11A Antibodies) has been described.
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
fms-related tyrosine kinase 3
, FL cytokine receptor-like
, FL cytokine receptor
, fetal liver kinase 2
, receptor-type tyrosine-protein kinase FLT3
, tyrosine-protein kinase FLT3
, tyrosine-protein kinase receptor flk-2
, CD135 antigen
, fms-like tyrosine kinase 3
, growth factor receptor tyrosine kinase type III
, stem cell tyrosine kinase 1
, FMS-like tyrosine kinase 3